| (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg) + Placebo for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Abbott Laboratories Infinity™ implantable deep brain stimulation system for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Accelerated theta-burst stimulation treatment for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Activa Tremor Control Sys (DBS Implant) for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| active rTMS treatment for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Behavioural Activation (BA) Therapy for depressive disorder, treatment-resistant | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Bilateral implantation of DBS system to Habeluna for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BPL-003 for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Deep Brain Stimulation for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Deep Brain Stimulation (DBS) for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Deep Brain Stimulation Model 3387 Model 3389 for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| deep brain stimulation with short & long pulse width for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Deep Brain Stimulation, implanted for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Deep brain stimulation(Active) + Deep brain stimulation(Sham) for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Deep Brain Stimulation(DBS) + Esketamine for depressive disorder, treatment-resistant | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Device: Directional Deep Brain Stimulation for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| edupression.com® for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Emono for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Escitalopram + Esketamine + Venlafaxine + Duloxetine + SERTRALINE for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Esketamine for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
|---|
| Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Esketamine Treatment as Usual (ESK) + Virtual-Reality-based mindfulness intervention for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Integration Therapy for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ketamine for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Ketamine Hydrochloride for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ketogenic Diet for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Medtronic Activa PC+S System for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Medtronic Activa SC DBS, Lead Model 3387 for depressive disorder, treatment-resistant | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Medtronic Percept PC DBS system for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Medtronic SenSight Directional DBS lead for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Medtronic Summit RC+S DBS system for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mindfulness-centered psilocybin-assisted therapy + Music-centered psilocybin-assisted therapy + Psilocybin for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nitrous Oxide for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
|---|
| Oculus VR headset for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Olanzapine and Fluoxetine combination (OFC) for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo + Escitalopram + Venlafaxine + Duloxetine + SERTRALINE for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo of trazodone + Psilocybin for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Psilocybin for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 8 |
|---|
| Randomized, staggered withdrawal phase for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SSRI/SNRI + Esketamine for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®) with the Magnus Neuromodulation System for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| tDCS for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Trazodone 5mg + Psilocybin for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|